ID   Abcam A-549 TGM2 KO 1
AC   CVCL_B1I0
SY   Human TGM2 (Transglutaminase 2) knockout A549
DR   Abcam; ab261876
DR   cancercelllines; CVCL_B1I0
DR   Wikidata; Q110430327
RX   PubMed=39220380;
CC   Population: Caucasian.
CC   Knockout cell: Method=CRISPR/Cas9; HGNC; HGNC:11778; TGM2.
CC   Sequence variation: Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0023 ! A-549
SX   Male
AG   58Y
CA   Cancer cell line
DT   Created: 16-12-21; Last updated: 10-04-25; Version: 7
//
RX   PubMed=39220380; DOI=10.12688/f1000research.150684.2; PMCID=PMC11362715;
RA   Ayoubi R., Fotouhi M., Alende C., Gonzalez Bolivar S., Southern K.,
RA   Laflamme C.;
RG   ABIF Consortium;
RG   NeuroSGC/YCharOS/EDDU Collaborative Group;
RT   "A guide to selecting high-performing antibodies for protein-glutamine
RT   gamma-glutamyltransferase 2 (TGM2) for use in western blot,
RT   immunoprecipitation and immunofluorescence.";
RL   F1000Research 13:481.1-481.19(2024).
//